Was the NBIX share gift by Stephen A. Sherwin a market transaction?

No. The footnote explains that the transaction represents a gift/charitable contribution and explicitly states it is not a market transaction. It further notes that no value was received for the gifted shares.

Neurocrine director gifts 1,000 company shares

Q: What insider transaction did NBIX director Stephen A. Sherwin report?

Stephen A. Sherwin reported a bona fide gift of 1,000 shares of Neurocrine Biosciences Common Stock effective September 2, 2026, described as a gift/charitable contribution with no value received and not conducted as a market transaction.

Q: How many NBIX shares did Stephen A. Sherwin gift in this Form 4?

Stephen A. Sherwin gifted 1,000 shares of Neurocrine Biosciences Common Stock. The transaction is described as a bona fide gift and a gift/charitable contribution effective September 2, 2026, with no value received for the transferred shares.

Q: How many NBIX shares does Stephen A. Sherwin hold after the reported gift?

After the reported gift, Stephen A. Sherwin directly holds 14,860 shares of Neurocrine Biosciences Common Stock, as stated in the filing’s post-transaction ownership information.

Q: Was Stephen A. Sherwin’s NBIX share gift made under a Rule 10b5-1 trading plan?

No. The document-level Rule 10b5-1 checkbox is not selected, so no Rule 10b5-1 trading plan is reported in connection with this 1,000-share gift of Neurocrine Biosciences stock.

Director Stephen A. Sherwin made a 1,000-share charitable gift of NBIX stock, leaving him with 14,860 directly held shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) director Stephen A. Sherwin reported a disposition of company shares through a bona fide gift of 1,000 shares of Common Stock effective September 2, 2026. According to the filing, this was a gift/charitable contribution, not a market transaction, and no value was received for the shares.

Following this charitable transfer, Sherwin directly holds 14,860 shares of Neurocrine Biosciences Common Stock. No Rule 10b5-1 trading plan is reported in connection with this transaction.

Insider Trade Summary

1,000 shares gifted

Gift 1 txn

Insider SHERWIN STEPHEN A

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock ^F1	1,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 14,860 shares (Direct)

Footnotes (1)

F1. This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Key Figures

Shares gifted: 1,000 shares Shares held after transaction: 14,860 shares Value received for gifted shares: $0

3 metrics

Shares gifted 1,000 shares Bona fide gift of Common Stock effective September 2, 2026

Shares held after transaction 14,860 shares Direct holdings of Stephen A. Sherwin after the gift

Value received for gifted shares $0 Footnote states no value was received for the 1,000-share gift

Key Terms

gift/charitable contribution, market transaction, bona fide gift

3 terms

gift/charitable contribution financial

"This transaction represents a gift/charitable contribution effective September 2, 2026."

market transaction financial

"This is not a market transaction, thus no price has been reported."

bona fide gift financial

"The filing describes the disposition as a bona fide gift of shares."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

FAQ

What insider transaction did NBIX director Stephen A. Sherwin report?

Stephen A. Sherwin reported a bona fide gift of 1,000 shares of Neurocrine Biosciences Common Stock effective September 2, 2026, described as a gift/charitable contribution with no value received and not conducted as a market transaction.

How many NBIX shares did Stephen A. Sherwin gift in this Form 4?

Stephen A. Sherwin gifted 1,000 shares of Neurocrine Biosciences Common Stock. The transaction is described as a bona fide gift and a gift/charitable contribution effective September 2, 2026, with no value received for the transferred shares.

How many NBIX shares does Stephen A. Sherwin hold after the reported gift?

After the reported gift, Stephen A. Sherwin directly holds 14,860 shares of Neurocrine Biosciences Common Stock, as stated in the filing’s post-transaction ownership information.

Did Neurocrine Biosciences director Stephen A. Sherwin receive any value for the gifted NBIX shares?

No. The filing states that the 1,000-share transaction represents a gift/charitable contribution and that no value was received for the gifted shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 09:40 PM Accepted by SEC EDGAR 09/03/2026 - 09:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERWIN STEPHEN A

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/02/2026		G⁽¹⁾		1,000	D	$0	14,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR